PB1938: 4WHIM: EVALUATING MAVORIXAFOR, AN ORAL CXCR4 ANTAGONIST, IN PATIENTS WITH WHIM SYNDROME VIA A GLOBAL PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL WITH OPEN-LABEL EXTENSION
Main Authors: | D. C. Dale, L. Alsina, A. Azar, R. Badolato, Y. Bertrand, A. Deya, K. E. Dickerson, N. Ezra, H. Hasle, H. J. Kang, S. Kiani-Alikhan, T. Kuijpers, A. Kulagin, D. Langguth, C. Levin, O. Neth, J. Peake, C. E. Rutten, A. Shcherbina, T. K. Tarrant, M. G. Vossen, C. A. Wysocki, A. Belschner, D. Cadavid, Y. Hu, H. Jiang, R. MacLeod, W. Tang, M. Tillinger, J. Donadieu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-06-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/01.HS9.0000850592.82147.9b |
Similar Items
-
S180: RESULTS OF A PHASE 3 TRIAL OF AN ORAL CXCR4 ANTAGONIST, MAVORIXAFOR, FOR TREATMENT OF PATIENTS WITH WHIM SYNDROME
by: Raffaele Badolato, et al.
Published: (2023-08-01) -
Enlightened Deception: An Analysis of Slavery in Maria Edgeworth’s <em>Whim for Whim </em>(1798)
by: Carmen Fernández Rodríguez
Published: (2017-06-01) -
Sex allocation: At the females' whim.
by: Sheldon, B
Published: (1999) -
The complex nature of CXCR4 mutations in WHIM syndrome
by: José Miguel Rodríguez-Frade, et al.
Published: (2024-07-01) -
Disease progression of WHIM syndrome in an international cohort of 66 pediatric and adult patients
by: Geier, CB, et al.
Published: (2022)